- Home
- EVAX vs MTVA Comparison
EVAX vs MTVA Comparison
Compare EVAX & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- MTVA
- Stock Information
- Founded
- EVAX 2008
- MTVA 2014
- Country
- EVAX Denmark
- MTVA United States
- Employees
- EVAX N/A
- MTVA N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- MTVA
- Sector
- EVAX Health Care
- MTVA
- Exchange
- EVAX Nasdaq
- MTVA NYSE
- Market Cap
- EVAX 15.1M
- MTVA 14.3M
- IPO Year
- EVAX 2021
- MTVA N/A
- Fundamental
- Price
- EVAX $2.64
- MTVA $0.70
- Analyst Decision
- EVAX Strong Buy
- MTVA Strong Buy
- Analyst Count
- EVAX 2
- MTVA 2
- Target Price
- EVAX $10.00
- MTVA $7.50
- AVG Volume (30 Days)
- EVAX 101.0K
- MTVA 110.1K
- Earning Date
- EVAX 08-13-2025
- MTVA 08-13-2025
- Dividend Yield
- EVAX N/A
- MTVA N/A
- EPS Growth
- EVAX N/A
- MTVA N/A
- EPS
- EVAX N/A
- MTVA N/A
- Revenue
- EVAX $3,293,000.00
- MTVA N/A
- Revenue This Year
- EVAX N/A
- MTVA N/A
- Revenue Next Year
- EVAX N/A
- MTVA N/A
- P/E Ratio
- EVAX N/A
- MTVA N/A
- Revenue Growth
- EVAX 2555.64
- MTVA N/A
- 52 Week Low
- EVAX $1.20
- MTVA $0.60
- 52 Week High
- EVAX $17.75
- MTVA $5.16
- Technical
- Relative Strength Index (RSI)
- EVAX 55.56
- MTVA N/A
- Support Level
- EVAX $2.26
- MTVA N/A
- Resistance Level
- EVAX $2.60
- MTVA N/A
- Average True Range (ATR)
- EVAX 0.21
- MTVA 0.00
- MACD
- EVAX -0.02
- MTVA 0.00
- Stochastic Oscillator
- EVAX 51.32
- MTVA 0.00
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.